In Situハイブリダイゼーション市場：技術、用途、エンドユーザー、地域別、2024年～2031年

In Situハイブリダイゼーション市場の評価、2024年～2031年

In Situハイブリダイゼーション（ISH）のニーズが高まっている背景には、がんを含む数多くの疾患の検出と調査におけるその重要性があります。ISHは、科学者や医療従事者が組織スライス内の特定の核酸配列を同定できる高度な技術です。この技術は、遺伝子の異常、感染性物質、特定の遺伝子の発現を自然組織内で検出するために不可欠です。がんやその他の遺伝性疾患の発生率が上昇するにつれ、ISHのような精密で信頼できる診断方法の必要性が高まり、市場は2024年に18億1,000万米ドルの収益を突破し、2031年には約33億8,000万米ドルの評価額に達します。

ISHと免疫組織化学や次世代シーケンシングのような他の最新の診断技術を組み合わせることで、疾患の病態生理についてより包括的な洞察が得られます。この包括的な方法は、個々の患者に合わせた治療を行うために広範な分子プロファイリングが不可欠な個別化医療において特に有用です。その結果、臨床診断、トランスレーショナルリサーチ、創薬におけるISH調査の用途が拡大し、ヘルスケアおよびバイオテクノロジー業界における需要が高まっており、2024年～2031年の間に8.97％のCAGRで成長する見込みです。

In Situハイブリダイゼーション市場定義/概要

In Situハイブリダイゼーション（ISH）は、組織セグメントや細胞などのサンプル内のDNAまたはRNAの特定の配列を検出するための効果的な科学技術です。In Situ "というフレーズは"In Situに"という意味で、この技術により科学者は生物学的環境内のこれらの遺伝子要素の特定の位置をピンポイントで特定することができます。基本的に、ISHによって研究者は特定の遺伝子やその活性（RNAの形で）が組織の細胞のどこにあるかを見ることができ、遺伝子発現パターンや細胞機能についての重要な洞察を得ることができます。

In situハイブリダイゼーションは、空間的情報と分子的情報の両方を提供できることから、研究や医療診断に頻繁に利用されています。その主な応用のひとつは発生生物学の分野で、生物の成長と発生を通して遺伝子がどのように制御され発現しているかを理解するのに役立っています。

ISHの将来的な応用は、医療診断や研究を含む様々な分野に変革をもたらすと期待されています。最も興味をそそられる将来の用途の一つは、個別化医療です。ヘルスケア分野がより個別化された治療戦略へとシフトする中、ISHはがんを含む様々な病気に関連する特定の遺伝子マーカーを発見する上で重要な役割を果たすことができます。

遺伝子疾患とがんの発生率の増加はIn Situハイブリダイゼーション市場を牽引するか？

遺伝性疾患とがんの発生率の増加は、In Situハイブリダイゼーション（ISH）ビジネスの主要な促進要因です。世界保健機関（WHO）によると、がんは2020年までに約1,000万人が死亡する世界第2位の死因です。世界のがん罹患率の上昇に伴い、信頼性の高い腫瘍の検出と特徴付けのためにISHのような最新の診断技術の使用が必要とされています。米国国立がん研究所は、男女の39.5％が生涯のある時点でがんと診断されると推定しています。この高い生涯リスクは、ISHのような精密診断技術の必要性が高まっていることを強調しています。

また、個別化治療や標的薬が重視されるようになったことも、ISH市場の拡大に貢献しています。米国国立衛生研究所（NIH）によれば、遺伝医学の開発により、がんを含む様々な疾患に対して300以上のオーダーメイド薬が開発されています。ISH技術は、治療法の決定や患者の転帰を予測するための遺伝子マーカーやバイオマーカーを見つけるために不可欠です。さらに、遺伝病やがんに罹りやすい高齢者人口の拡大が、ISH技術の需要を高めています。国連は、2050年までに世界の6人に1人が65歳を超えると予測しており、これは2019年の11人に1人から増加します。

熟練専門家の不足はIn Situハイブリダイゼーション市場の妨げになるか？

有能な専門家の不足はIn Situハイブリダイゼーション（ISH）市場に影響を与える可能性があります。しかし、多くの要因がこの懸念を相殺するのに役立つと思われます。第一に、精密医療と個別化ヘルスケアが重視されるようになり、ISHのような分子診断ツールの需要が高まっています。米国国立衛生研究所によれば、プレシジョン・メディシン・イニシアチブは、個別化治療の必要性を強調する全国規模の研究コホートに100万人以上のボランティアを登録する意向です。この傾向は、より多くの専門家が関連職種に特化することを確実に促すと思われます。さらに、自動化された装置や合理化されたプロトコルの作成など、ISH技術の進歩は、このアプローチをより広範囲の検査室職員にとってより利用しやすいものにしています。

さらに、教育機関や業界団体も積極的にスキルギャップを埋めようとしています。米国臨床病理学会（ASCP）は、2013年から2018年の間に認定プログラムを修了した検査室専門家の数が7.1％増加したと報告しています。さらに、米国労働統計局は、医療検査技師および臨床検査技師の仕事は、2019年から2029年の間に全体平均よりも早く7％拡大すると予測しています。この増加は、ISH手技を専門とする潜在的な専門家のプールが拡大していることを示しています。さらに、クロストレーニング・プログラムや継続教育の機会が一般的になりつつあり、現在の検査室の従業員がスキルセットの幅を広げることを可能にしています。

目次

第1章 イントロダクション

• 市場の定義
• 市場セグメンテーション
• 調査手法

第2章 エグゼクティブサマリー

• 主な調査結果
• 市場概要
• 市場ハイライト

第3章 市場概要

• 市場規模と成長の可能性
• 市場動向
• 市場促進要因
• 市場抑制要因
• 市場機会
• ポーターのファイブフォース分析

第4章 In Situハイブリダイゼーション市場：技術別

• 蛍光In Situハイブリダイゼーション（FISH）
• 発色In Situハイブリダイゼーション（CISH）
• 放射性In Situハイブリダイゼーション（RISH）

第5章 In Situハイブリダイゼーション市場：用途別

• がん診断と調査
• 神経科学
• 感染症診断
• 出生前検査
• 創薬と開発

第6章 In Situハイブリダイゼーション市場：エンドユーザー別

• 病院および診断研究所
• バイオ医薬品企業
• 学術・研究機関

第7章 地域別分析

• 北米
• 米国
• カナダ
• メキシコ
• 欧州
• 英国
• ドイツ
• フランス
• イタリア
• アジア太平洋
• 中国
• 日本
• インド
• オーストラリア
• ラテンアメリカ
• ブラジル
• アルゼンチン
• チリ
• 中東・アフリカ
• 南アフリカ
• サウジアラビア
• アラブ首長国連邦

第8章 市場力学

• 市場促進要因
• 市場抑制要因
• 市場機会
• COVID-19の市場への影響

第9章 競合情勢

• 主要企業
• 市場シェア分析

第10章 企業プロファイル

• Abbott Laboratories
• Agilent Technologies
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Illumina Inc.
• PerkinElmer Inc.
• NanoString Technologies Inc.
• Advanced Cell Diagnostics Inc.
• Leica Biosystems GmbH
• DiaGenode SA

第11章 市場の展望と機会

• 新興技術
• 今後の市場動向
• 投資機会

第12章 付録

• 略語リスト
• 出典と参考文献

In Situ Hybridization Market Valuation - 2024-2031

The growing need for In Situ Hybridization (ISH) is motivated by its importance in detecting and researching numerous diseases including cancer. ISH is a sophisticated technology that enables scientists and medical practitioners to identify specific nucleic acid sequences within tissue slices. This skill is critical for detecting genetic anomalies, infectious agents, and the expression of certain genes in their natural tissue context. As the incidence of cancer and other genetic illnesses rises, the necessity for precise and dependable diagnostic methods like ISH grows by enabling the market to surpass a revenue of USD 1.81 Billion valued in 2024 and reach a valuation of around USD 3.38 Billion by 2031.

The combination of ISH and other modern diagnostic techniques such as immunohistochemistry and next-generation sequencing is yielding more comprehensive insights into disease pathophysiology. This comprehensive method is especially useful in personalized medicine where extensive molecular profiling is essential for personalizing treatments to individual patients. As a result, ISH's rising applications in clinical diagnostics, translational research, and drug discovery are driving up demand in the healthcare and biotechnology industries by enabling the market to grow at aCAGR of 8.97% from 2024 to 2031.

In Situ Hybridization Market: Definition/ Overview

In situ hybridization (ISH) is an effective scientific technique for detecting specific sequences of DNA or RNA within a sample such as a tissue segment or a cell. The phrase "in situ" means "in place," implying that this technology enables scientists to pinpoint the specific location of these genetic elements inside the biological milieu. Essentially, ISH allows researchers to see where certain genes or their activity (in the form of RNA) are situated in a tissue's cells providing vital insights into gene expression patterns and cellular function.

In situ hybridization is frequently utilized in research and medical diagnostics because of its ability to offer both spatial and molecular information. One of its key applications is in the field of developmental biology where it assists scientists in understanding how genes are regulated and expressed throughout organismal growth and development.

The future application of ISH is expected to transform a variety of disciplines including medical diagnostics and research. One of the most intriguing future uses is personalized medicine. As the healthcare sector shifts toward more personalized treatment strategies, ISH can play an important role in discovering specific genetic markers linked to various diseases including cancer.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Rising Incidence of Genetic Disorders and Cancer Drive the In Situ Hybridization Market?

The increasing incidence of genetic diseases and cancer is a major driver of the in situ hybridization (ISH) business. According to the World Health Organization (WHO), cancer is the world's second biggest cause of death accounting for roughly 10 million deaths by 2020. The rising global cancer incidence needs the use of modern diagnostic techniques such as ISH for reliable tumor detection and characterization. The National Cancer Institute estimates that 39.5% of men and women will be diagnosed with cancer at some point in their lives. This high lifetime risk highlights the increasing need for precise diagnostic techniques like ISH.

The growing emphasis on individualized treatment and targeted medicines also helps to expand the ISH market. The National Institutes of Health (NIH) says that developments in genetic medicine have resulted in the development of over 300 tailored drugs for a variety of disorders including cancer. ISH techniques are critical for finding genetic markers and biomarkers that inform therapy decisions and predict patient outcomes. Furthermore, the expanding older population which is more vulnerable to genetic illnesses and cancer increases the demand for ISH technology. The United Nations projects that by 2050, one in every six persons worldwide will be beyond the age of 65, up from one in every eleven in 2019.

Will Shortage of Skilled Professionals Hamper the In Situ Hybridization Market?

A shortage of competent specialists could influence the in situ hybridization (ISH) market; however, numerous factors may help to offset this concern. First, the growing emphasis on precision medicine and individualized healthcare is increasing demand for molecular diagnostic tools such as ISH. According to the National Institutes of Health, the Precision Medicine Initiative intends to enroll 1 million or more volunteers in a national study cohort emphasizing the need for personalized treatment procedures. This tendency will certainly encourage more professionals to specialize in related professions. Furthermore, advances in ISH technology such as the creation of automated equipment and streamlined protocols are making the approach more accessible to a wider spectrum of laboratory personnel.

Additionally, educational institutions and industry associations are actively attempting to close the skills gap. The American Society for Clinical Pathology (ASCP) reported a 7.1% rise in the number of laboratory professionals who completed certification programs between 2013 and 2018. Furthermore, the U.S. Bureau of Labor Statistics predicts that medical and clinical laboratory technologist and technician jobs will expand by 7% between 2019 and 2029 faster than the overall average. This increase indicates an expanding pool of potential specialists who could specialize in ISH procedures. Furthermore, cross-training programs and continuing education opportunities are becoming more common allowing current laboratory employees to broaden their skill sets.

Category-Wise Acumens

Will the Development of Advanced Fluorescent Dyes and Imaging Technologies Influence the Technique Segment?

Fluorescent chromogenic in situ hybridization (CISH) is also an important technique, however it is less prevalent than FISH. CISH employs chromogenic substrates to provide a visible color reaction that is persistent and easy to interpret using a conventional light microscope. This method is especially useful in pathology laboratories for tissue-based analysis where persistent staining is required for long-term storage and examination of samples. While CISH has advantages in terms of visibility and ease of use, it does not match FISH's multiplexing capability and sensitivity.

In Situ, Hybridization (FISH) is currently the most common technique. FISH's extensive adoption and supremacy can be due to its great sensitivity, adaptability, and ability to perform multiplexing. This technology uses fluorescently labeled probes that bind to specific nucleic acid sequences within cells or tissues allowing researchers and physicians to observe and evaluate several targets at the same time using sophisticated fluorescence microscopy. FISH is especially useful in cytogenetics, where it is used to detect chromosomal abnormalities, and in cancer research to find genetic alterations and gene amplifications. Its ability to produce precise and consistent results makes it a popular choice in both clinical diagnosis and research contexts.

Will the Increasing Demand for Oncological Research and Clinical Practice Drive Growth in the Application Segment?

The demand for in situ hybridization for cancer diagnosis and research is one of the primary applications. This dominance stems from ISH's crucial role in detecting and defining specific genetic changes linked to distinct malignancies. Cancer research and diagnosis greatly benefit from ISH's capacity to detect gene amplifications, translocations, and biomarker expression levels in tissue samples. For example, ISH techniques are critical for identifying malignancies such as breast cancer as they can detect HER2 gene amplifications and guide therapy options. The rising global prevalence of cancer combined with a growing emphasis on individualized care fuels the demand for precise and dependable diagnostic techniques such as ISH. Furthermore, advances in ISH technology have improved its potential to deliver deep molecular insights which are critical for creating targeted medicines and improving patient outcomes.

Neuroscience is another important application, however not as prevalent as cancer diagnosis. ISH is used in neuroscience to analyze gene expression patterns in the brain and nervous system which is critical for understanding neurological illnesses and brain development. Researchers utilize ISH to map gene expression in different brain regions revealing information about illnesses including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The detailed spatial resolution of ISH enables scientists to explore how specific genes influence brain function and pathology, hence contributing to the creation of new treatments. While neurology is a rising and essential sector for ISH applications, cancer diagnosis remains the principal market driver owing to the urgent and high-impact clinical demand for precise and actionable cancer-related genetic information.

Country/Region-wise Acumens

Will Technologically Upgraded Infrastructure Drive the Growth in the North American Region?

The in situ hybridization (ISH) market in North America is expected to grow significantly owing mostly to technical advancements in infrastructure. The region's rising cancer prevalence is a significant driver. The American Cancer Society estimates that in 2023, there will be 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States alone. Given the high incidence rate, improved diagnostic approaches such as ISH are required for reliable detection and treatment planning. Furthermore, the expanding use of personalized medicine approaches is increasing the demand for ISH procedures. According to the National Institutes of Health, precision medicine programs have garnered more than USD 200 Million in funding since 2015, demonstrating the value of personalized therapy tactics.

Another key contributor is North America's strong research and development infrastructure. The United States leads the world in biomedical research funding with the National Institutes of Health budget reaching USD 45 Billion by 2021. This significant investment encourages advancements in ISH technologies and applications. Furthermore, the presence of large pharmaceutical and biotechnology companies in the region helps to drive market expansion. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the US biopharmaceutical sector will invest an estimated USD 102.3 Billion in R&D in 2021, with a large amount of that going toward developing and implementing advanced diagnostic technologies such as ISH. The region's supremacy in the ISH market is also due to its well-developed healthcare infrastructure and high healthcare spending.

Will the Investments by Manufacturers & Government Boost the Market in the Asia Pacific Region?

The Asia Pacific region is poised for significant growth in the in situ hybridization (ISH) market. According to the World Health Organization, new cancer cases in Asia are expected to increase from 8.8 million in 2018 to 11.5 million by 2025. This dangerous trend has spurred manufacturers and governments to make significant investments in advanced diagnostic technologies such as ISH. For example, the Japanese government has set aside approximately 46 billion yen (approximately USD 415 Million) on cancer research and development in its 2021 budget.

Another important driver is the rapid expansion of healthcare infrastructure and rising healthcare spending in emerging economies. The Indian government, for example, has stated plans to expand healthcare spending to 2.5% of GDP by 2025, up from 1.5% today. This increase in spending is anticipated to drive up the use of advanced diagnostic procedures such as ISH. Additionally, the increased emphasis on customized medicine and tailored therapies is driving up demand for ISH approaches. According to a report by the Asia Pacific Personalized Medicine Coalition, the region's personalized medicine market is predicted to develop at a CAGR of 15.6% from 2021-2026.

Competitive Landscape

The in situ hybridization market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the in situ hybridization market include:

Thermo Fisher Scientific, Inc.

Abbott

PerkinElmer, Inc.

BioView

Agilent Technologies, Inc.

Merck KGaA

Bio-Rad Laboratories, Inc.

Latest Developments

In January 2023, Ikonisys SA teamed with Integrated Gulf Biosystems Group (IGB) to distribute the Ikoniscope20 Digital Fluorescence Microscope Solution in the Middle East, including Saudi Arabia, the UAE, Kuwait, Bahrain, and South Asian regions. This agreement intends to increase the reach of Ikonisys' oncology testing products.

In February 2023, Molecular Instruments, a spin-off of the California Institute of Technology introduced HCR RNA-CISH kits to improve automated chromogenic ISH procedures using RNAscope. These kits enable a double turnaround time at half the cost.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. In Situ Hybridization Market, By Technique

• Fluorescent In Situ Hybridization (FISH)
• Chromogenic In Situ Hybridization (CISH)
• Radioactive In Situ Hybridization (RISH)

5. In Situ Hybridization Market, By Application

• Cancer Diagnosis and Research
• Neuroscience
• Infectious Disease Diagnosis
• Prenatal Testing
• Drug Discovery and Development

6. In Situ Hybridization Market, By End-User

• Hospitals and Diagnostic Laboratories
• Biopharmaceutical Companies
• Academic and Research Institutes

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Abbott Laboratories
• Agilent Technologies
• F. Hoffmann-La Roche Ltd
• Merck KGaA
• Illumina Inc.
• PerkinElmer Inc.
• NanoString Technologies Inc.
• Advanced Cell Diagnostics Inc.
• Leica Biosystems GmbH
• DiaGenode SA

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References